Search

Your search keyword '"Mikhailidis, Dimitri P."' showing total 3,394 results
Start Over Author "Mikhailidis, Dimitri P."
3,394 results on '"Mikhailidis, Dimitri P."'

1. New-Onset Diabetes Mellitus in COVID-19: A Scoping Review

Author

Pantea Stoian, Anca, Bica, Ioana-Cristina, Salmen, Teodor, Al Mahmeed, Wael, Al-Rasadi, Khalid, Al-Alawi, Kamila, Banach, Maciej, Banerjee, Yajnavalka, Ceriello, Antonio, Cesur, Mustafa, Cosentino, Francesco, Firenze, Alberto, Galia, Massimo, Goh, Su-Yen, Janez, Andrej, Kalra, Sanjay, Kapoor, Nitin, Kempler, Peter, Lessan, Nader, Lotufo, Paulo, Mikhailidis, Dimitri P., Nibali, Luigi, Papanas, Nikolaos, Powell-Wiley, Tiffany, Rizvi, Ali A., Sahebkar, Amirhossein, Santos, Raul D., Toth, Peter P., Viswanathan, Vijay, and Rizzo, Manfredi

Published
2024
Full Text
View/download PDF

2. Correction to: New-Onset Diabetes Mellitus in COVID-19: A Scoping Review

Author

Pantea Stoian, Anca, Bica, Ioana-Cristina, Salmen, Teodor, Al Mahmeed, Wael, Al-Rasadi, Khalid, Al-Alawi, Kamila, Banach, Maciej, Banerjee, Yajnavalka, Ceriello, Antonio, Cesur, Mustafa, Cosentino, Francesco, Firenze, Alberto, Galia, Massimo, Goh, Su-Yen, Janez, Andrej, Kalra, Sanjay, Kapoor, Nitin, Kempler, Peter, Lessan, Nader, Lotufo, Paulo, Mikhailidis, Dimitri P., Nibali, Luigi, Papanas, Nikolaos, Powell-Wiley, Tiffany, Rizvi, Ali A., Sahebkar, Amirhossein, Santos, Raul D., Toth, Peter P., Viswanathan, Vijay, and Rizzo, Manfredi

Published
2024
Full Text
View/download PDF

4. Prevalence of statin intolerance: a meta-analysis

Author

Bytyçi, Ibadete, Penson, Peter E, Mikhailidis, Dimitri P, Wong, Nathan D, Hernandez, Adrian V, Sahebkar, Amirhossein, Thompson, Paul D, Mazidi, Mohsen, Rysz, Jacek, Pella, Daniel, Reiner, Željko, Toth, Peter P, and Banach, Maciej

Subjects
Heart Disease, Cardiovascular, Prevention, Atherosclerosis, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lipids, Male, Prevalence, Randomized Controlled Trials as Topic, Risk Factors, Cardiovascular disease, Risk factors, Statin intolerance, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

AimsStatin intolerance (SI) represents a significant public health problem for which precise estimates of prevalence are needed. Statin intolerance remains an important clinical challenge, and it is associated with an increased risk of cardiovascular events. This meta-analysis estimates the overall prevalence of SI, the prevalence according to different diagnostic criteria and in different disease settings, and identifies possible risk factors/conditions that might increase the risk of SI.Methods and resultsWe searched several databases up to 31 May 2021, for studies that reported the prevalence of SI. The primary endpoint was overall prevalence and prevalence according to a range of diagnostic criteria [National Lipid Association (NLA), International Lipid Expert Panel (ILEP), and European Atherosclerosis Society (EAS)] and in different disease settings. The secondary endpoint was to identify possible risk factors for SI. A random-effects model was applied to estimate the overall pooled prevalence. A total of 176 studies [112 randomized controlled trials (RCTs); 64 cohort studies] with 4 143 517 patients were ultimately included in the analysis. The overall prevalence of SI was 9.1% (95% confidence interval 8.0-10%). The prevalence was similar when defined using NLA, ILEP, and EAS criteria [7.0% (6.0-8.0%), 6.7% (5.0-8.0%), 5.9% (4.0-7.0%), respectively]. The prevalence of SI in RCTs was significantly lower compared with cohort studies [4.9% (4.0-6.0%) vs. 17% (14-19%)]. The prevalence of SI in studies including both primary and secondary prevention patients was much higher than when primary or secondary prevention patients were analysed separately [18% (14-21%), 8.2% (6.0-10%), 9.1% (6.0-11%), respectively]. Statin lipid solubility did not affect the prevalence of SI [4.0% (2.0-5.0%) vs. 5.0% (4.0-6.0%)]. Age [odds ratio (OR) 1.33, P = 0.04], female gender (OR 1.47, P = 0.007), Asian and Black race (P 4 million patients, the prevalence of SI is low when diagnosed according to international definitions. These results support the concept that the prevalence of complete SI might often be overestimated and highlight the need for the careful assessment of patients with potential symptoms related to SI.

Published
2022

5. Artificial intelligence for cardiovascular disease risk assessment in personalised framework: a scoping review

Author

Singh, Manasvi, Kumar, Ashish, Khanna, Narendra N., Laird, John R., Nicolaides, Andrew, Faa, Gavino, Johri, Amer M., Mantella, Laura E., Fernandes, Jose Fernandes E., Teji, Jagjit S., Singh, Narpinder, Fouda, Mostafa M., Singh, Rajesh, Sharma, Aditya, Kitas, George, Rathore, Vijay, Singh, Inder M., Tadepalli, Kalyan, Al-Maini, Mustafa, Isenovic, Esma R., Chaturvedi, Seemant, Garg, Deepak, Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Viswanathan, Vijay, Kalra, Manudeep K., Ruzsa, Zoltan, Saba, Luca, Laine, Andrew F., Bhatt, Deepak L., and Suri, Jasjit S.

Published
2024
Full Text
View/download PDF

6. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).

Author

Penson, Peter E, Bruckert, Eric, Marais, David, Reiner, Željko, Pirro, Matteo, Sahebkar, Amirhossein, Bajraktari, Gani, Mirrakhimov, Erkin, Rizzo, Manfredi, Mikhailidis, Dimitri P, Sachinidis, Alexandros, Gaita, Dan, Latkovskis, Gustavs, Mazidi, Mohsen, Toth, Peter P, Pella, Daniel, Alnouri, Fahad, Postadzhiyan, Arman, Yeh, Hung-I, Mancini, GB John, von Haehling, Stephan, Banach, Maciej, and International Lipid Expert Panel (ILEP)

Subjects
International Lipid Expert Panel, Muscles, Humans, Muscular Diseases, Lipids, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Nocebo Effect, Drucebo effect, Nocebo effect, SAMS, Statin intolerance, Pain Research, Patient Safety, Clinical Research, 6.1 Pharmaceuticals, 7.3 Management and decision making, Management of diseases and conditions, Evaluation of treatments and therapeutic interventions, Musculoskeletal, Physiology, Clinical Sciences, Human Movement and Sports Sciences
Abstract

Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3-5%). Many perceived AEs are misattributed (e.g. physical musculoskeletal injury and inflammatory myopathies), and subjective symptoms occur as a result of the fact that patients expect them to do so when taking medicines (the nocebo/drucebo effect)-what might be truth even for over 50% of all patients with muscle weakness/pain. Clear guidance is necessary to enable the optimal management of plasma in real-world clinical practice in patients who experience subjective AEs. In this Position Paper of the International Lipid Expert Panel (ILEP), we present a step-by-step patient-centred approach to the identification and management of SAMS with a particular focus on strategies to prevent and manage the nocebo/drucebo effect and to improve long-term compliance with lipid-lowering therapy.

Published
2022

8. Recent advances and controversial issues in the optimal management of asymptomatic carotid stenosis

Author

Paraskevas, Kosmas I., Brown, Martin M., Lal, Brajesh K., Myrcha, Piotr, Lyden, Sean P., Schneider, Peter A., Poredos, Pavel, Mikhailidis, Dimitri P., Secemsky, Eric A., Musialek, Piotr, Mansilha, Armando, Parikh, Sahil A., Silvestrini, Mauro, Lavie, Carl J., Dardik, Alan, Blecha, Matthew, Liapis, Christos D., Zeebregts, Clark J., Nederkoorn, Paul J., Poredos, Peter, Gurevich, Victor, Jawien, Arkadiusz, Lanza, Gaetano, Gray, William A., Gupta, Ajay, Svetlikov, Alexei V., Fernandes e Fernandes, Jose, Nicolaides, Andrew N., White, Christopher J., Meschia, James F., Cronenwett, Jack L., Schermerhorn, Marc L., and AbuRahma, Ali F.

Published
2024
Full Text
View/download PDF

9. An international, multispecialty, expert-based Delphi Consensus document on controversial issues in the management of patients with asymptomatic and symptomatic carotid stenosis

Author

Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Ringleb, Peter Arthur, Brown, Martin M., Dardik, Alan, Poredos, Pavel, Gray, William A., Nicolaides, Andrew N., Lal, Brajesh K., Mansilha, Armando, Antignani, Pier Luigi, de Borst, Gert J., Cambria, Richard P., Loftus, Ian M., Lavie, Carl J., Blinc, Ales, Lyden, Sean P., Matsumura, Jon S., Jezovnik, Mateja K., Bacharach, J. Michael, Meschia, James F., Clair, Daniel G., Zeebregts, Clark J., Lanza, Gaetano, Capoccia, Laura, Spinelli, Francesco, Liapis, Christos D., Jawien, Arkadiusz, Parikh, Sahil A., Svetlikov, Alexei, Menyhei, Gabor, Davies, Alun H., Musialek, Piotr, Roubin, Gary, Stilo, Francesco, Sultan, Sherif, Proczka, Robert M., Faggioli, Gianluca, Geroulakos, George, Fernandes e Fernandes, Jose, Ricco, Jean-Baptiste, Saba, Luca, Secemsky, Eric A., Pini, Rodolfo, Myrcha, Piotr, Rundek, Tatjana, Martinelli, Ombretta, Kakkos, Stavros K., Sachar, Ravish, Goudot, Guillaume, Schlachetzki, Felix, Lavenson, George S., Jr., Ricci, Stefano, Topakian, Raffi, Millon, Antoine, Di Lazzaro, Vincenzo, Silvestrini, Mauro, Chaturvedi, Seemant, Eckstein, Hans-Henning, Gloviczki, Peter, and White, Christopher J.

Published
2024
Full Text
View/download PDF

10. Carotid Plaque-RADS: A Novel Stroke Risk Classification System

Author

Saba, Luca, Cau, Riccardo, Murgia, Alessandro, Nicolaides, Andrew N., Wintermark, Max, Castillo, Mauricio, Staub, Daniel, Kakkos, Stavros K., Yang, Qi, Paraskevas, Kosmas I., Yuan, Chun, Edjlali, Myriam, Sanfilippo, Roberto, Hendrikse, Jeroen, Johansson, Elias, Mossa-Basha, Mahmud, Balu, Niranjan, Dichgans, Martin, Saloner, David, Bos, Daniel, Jager, H. Rolf, Naylor, Ross, Faa, Gavino, Suri, Jasjit S., Costello, Justin, Auer, Dorothee P., Mcnally, J. Scott, Bonati, Leo H., Nardi, Valentina, van der Lugt, Aad, Griffin, Maura, Wasserman, Bruce A., Kooi, M. Eline, Gillard, Jonathan, Lanzino, Giuseppe, Mikhailidis, Dimitri P., Mandell, Daniel M., Benson, John C., van Dam-Nolen, Dianne H.K., Kopczak, Anna, Song, Jae W., Gupta, Ajay, DeMarco, J. Kevin, Chaturvedi, Seemant, Virmani, Renu, Hatsukami, Thomas S., Brown, Martin, Moody, Alan R., Libby, Peter, Schindler, Andreas, and Saam, Tobias

Published
2024
Full Text
View/download PDF

11. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

Author

Acosta, Julio, Al-Khnifsawi, Mutaz, Alnouri, Fahad, Amar, Fahma, Atanasov, Atanas G., Bajraktari, Gani, Banach, Maciej, Gouni-Berthold, Ioanna, Bhaskar, Sonu, Bielecka-Dąbrowa, Agata, Bjelakovic, Bojko, Bruckert, Eric, Bytyçi, Ibadete, Cafferata, Alberto, Ceska, Richard, Cicero, Arrigo F.G., Chlebus, Krzysztof, Collet, Xavier, Daccord, Magdalena, Descamps, Olivier, Djuric, Dragan, Durst, Ronen, Ezhov, Marat V., Fras, Zlatko, Gaita, Dan, Hernandez, Adrian V., Jones, Steven R., Jozwiak, Jacek, Kakauridze, Nona, Kallel, Amani, Katsiki, Niki, Khera, Amit, Kostner, Karam, Kubilius, Raimondas, Latkovskis, Gustavs, John Mancini, G.B., David Marais, A., Martin, Seth S., Martinez, Julio Acosta, Mazidi, Mohsen, Mikhailidis, Dimitri P., Mirrakhimov, Erkin, Miserez, Andre R., Mitchenko, Olena, Mitkovskaya, Natalya P., Moriarty, Patrick M., Mohammad Nabavi, Seyed, Nair, Devaki, Panagiotakos, Demosthenes B., Paragh, György, Pella, Daniel, Penson, Peter E., Petrulioniene, Zaneta, Pirro, Matteo, Postadzhiyan, Arman, Puri, Raman, Reda, Ashraf, Reiner, Željko, Radenkovic, Dina, Rakowski, Michał, Riadh, Jemaa, Richter, Dimitri, Rizzo, Manfredi, Ruscica, Massimiliano, Sahebkar, Amirhossein, Serban, Maria-Corina, Shehab, Abdullah M.A, Shek, Aleksandr B., Sirtori, Cesare R., Stefanutti, Claudia, Tomasik, Tomasz, Toth, Peter P., Viigimaa, Margus, Valdivielso, Pedro, Vinereanu, Dragos, Vohnout, Branislav, von Haehling, Stephan, Vrablik, Michal, Wong, Nathan D., Yeh, Hung-I, Zhisheng, Jiang, Zirlik, Andreas, Colletti, Alessandro, Mancini, John, Marais, David, Moriarty, Patrick, and Cicero, Arrigo Francesco Giuseppe

Published
2023
Full Text
View/download PDF

12. Why do guidelines recommend screening for abdominal aortic aneurysms, but not for asymptomatic carotid stenosis? A plea for a randomized controlled trial

Author

Paraskevas, Kosmas I., Spence, J. David, Mikhailidis, Dimitri P., Antignani, Pier Luigi, Gloviczki, Peter, Eckstein, Hans-Henning, Spinelli, Francesco, Stilo, Francesco, Saba, Luca, Poredos, Pavel, Dardik, Alan, Liapis, Christos D., Mansilha, Armando, Faggioli, Gianluca, Pini, Rodolfo, Jezovnik, Mateja K., Sultan, Sherif, Musiałek, Piotr, Goudot, Guillaume, Lavenson, George S., Jr, Jawien, Arkadiusz, Blinc, Aleš, Myrcha, Piotr, Fernandes e Fernandes, Jose, Geroulakos, George, Kakkos, Stavros K., Knoflach, Michael, Proczka, Robert M., Capoccia, Laura, Rundek, Tatjana, Svetlikov, Alexei S., Silvestrini, Mauro, Ricco, Jean-Baptiste, Davies, Alun H., Di Lazzaro, Vincenzo, Suri, Jasjit S., Lanza, Gaetano, Fraedrich, Gustav, Zeebregts, Clark J., and Nicolaides, Andrew N.

Published
2023
Full Text
View/download PDF

17. Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study

Author

Krzemień, Paweł, Kasperczyk, Sławomir, Banach, Maciej, Kasperczyk, Aleksandra, Dobrakowski, Michał, Tomasik, Tomasz, Windak, Adam, Mastej, Mirosław, Catapano, Alberico, Ray, Kausik K., Mikhailidis, Dimitri P., Toth, Peter P., Howard, George, Lip, Gregory Y. H., Tomaszewski, Maciej, Charchar, Fadi J., Sattar, Naveed, Williams, Bryan, MacDonald, Thomas M., Penson, Peter E., and Jóźwiak, Jacek J.

Published
2022
Full Text
View/download PDF

19. Optimal Management of Asymptomatic Carotid Stenosis in 2021: The Jury is Still Out. An International, Multispecialty, Expert Review and Position Statement

Author

Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Antignani, Pier Luigi, Baradaran, Hediyeh, Bokkers, Reinoud P.H., Cambria, Richard P., Dardik, Alan, Davies, Alun H., Eckstein, Hans-Henning, Faggioli, Gianluca, e Fernandes, Jose Fernandes, Fraedrich, Gustav, Geroulakos, George, Gloviczki, Peter, Golledge, Jonathan, Gupta, Ajay, Jezovnik, Mateja K., Kakkos, Stavros K., Katsiki, Niki, Knoflach, Michael, Kooi, M. Eline, Lanza, Gaetano, Liapis, Christos D., Loftus, Ian M., Mansilha, Armando, Millon, Antoine, Nicolaides, Andrew N., Pini, Rodolfo, Poredos, Pavel, Ricco, Jean-Baptiste, Riles, Thomas S., Ringleb, Peter Arthur, Rundek, Tatjana, Saba, Luca, Schlachetzki, Felix, Silvestrini, Mauro, Spinelli, Francesco, Stilo, Francesco, Sultan, Sherif, Suri, Jasjit S., Zeebregts, Clark J., and Chaturvedi, Seemant

Published
2022
Full Text
View/download PDF

20. Dietary patterns, plasma vitamins and Trans fatty acids are associated with peripheral artery disease

Author

Mazidi, Mohsen, Wong, Nathan D, Katsiki, Niki, Mikhailidis, Dimitri P, and Banach, Maciej

Subjects
Biomedical and Clinical Sciences, Nutrition and Dietetics, Prevention, Cardiovascular, Nutrition, Cancer, Complementary and Integrative Health, Clinical Research, Metabolic and endocrine, Adult, Aged, Ankle Brachial Index, Dietary Fats, Diterpenes, Fatty Acids, Unsaturated, Feeding Behavior, Female, Humans, Logistic Models, Male, Middle Aged, Nutrition Surveys, Odds Ratio, Oleic Acid, Peripheral Arterial Disease, Principal Component Analysis, Retinyl Esters, United States, Vitamin A, Vitamin D, Peripheral artery disease, Dietary patterns, Vitamins, Trans fatty acids, Other Information and Computing Sciences, Medical Biochemistry and Metabolomics, Nutrition & Dietetics, Medical biochemistry and metabolomics, Nutrition and dietetics
Abstract

BackgroundTo investigate the association between dietary patterns (DP), plasma vitamins and trans fatty acids (TFAs) with the likelihood of peripheral artery disease (PAD).MethodsNational Health and Nutrition Examination Survey (NHANES) data for the years 1999-2002 were used. PAD was diagnosed by ankle brachial index assessment. Plasma concentrations of vitamins were measured using high performance liquid chromatography. Vitamin D levels were measured by radioimmunoassay. Analysis of covariance, principal components analysis (PCA) and adjusted logistic regression were applied, accounting for the survey design and sample weights.ResultsOf the 4864 eligible participants, 2482 (51.0%) were men and 269 (5.5%) had prevalent PAD. PCA uncovered three DPs which accounted for 56.8% of the variance in dietary nutrients consumption including DP1 (fatty acids and cholesterol), DP2 (minerals, vitamins and fiber), and DP3 (polyunsaturated fatty acids [PUFA]). PAD patients had a significantly higher serum concentrations of trans 9-octadecenoic acid and trans 9, trans 12-octadienoic acid as well as lower plasma levels of vitamin D, retinol, retinyl stearate and retinyl palmitate (p

Published
2017

27. Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel

Author

Banach, Maciej, Gaita, Dan, Haluzik, Martin, Janez, Andrej, Kamenov, Zdravko, Kempler, Peter, Lalic, Nebojsa, Linhart, Ales, Mikhailidis, Dimitri P, Nocoń, Aleksandra, Silva Nunes, Jose, Papanas, Nikolaos, Raposo, Joao Filipe, Rizzo, Manfredi, and Pantea Stoian, Anca

Published
2021
Full Text
View/download PDF

30. Are We Using Ezetimibe As Much As We Should?

Author

Manolis, Antonis A, Manolis, Theodora A, Mikhailidis, Dimitri P, and Manolis, Antonis S

Subjects
EZETIMIBE, LDL cholesterol, STATINS (Cardiovascular agents), LOW density lipoproteins, CONTRAST media
Abstract

Lipid-lowering therapies, particularly non-statin regimens, are underutilized as ~2/3 of patients with atherosclerotic cardiovascular (CV) disease (CVD) are not optimally managed, and do not attain target low-density lipoprotein cholesterol (LDL-C) concentrations, despite statin treatment. Statins have been the mainstay of hypolipidemic therapies; however, they are plagued by adverse effects, which have partly hindered their more widespread use. Ezetimibe is often the first added mode of treatment to attain LDL-C goals as it is efficacious and also allows the use of a smaller dose of statin, while the need for more expensive therapies is obviated. We herein provide a comprehensive review of the effects of ezetimibe in lipid lowering and reducing CV events and improving outcomes. Of the hypolipidemic therapies, oral ezetimibe, in contrast to newer agents, is the most convenient and/or affordable regimen to be utilized as mono- or combined therapy supported by data from CV outcomes studies attesting to its efficacy in reducing CVD risk and events. When combined with a statin, the statin dose could be lower, thus curtailing side-effects, while the hypolipidemic effect is enhanced (by ~20%) as the percentage of patients with target level LDL-C (<70 mg/dL) is higher with combined treatment versus a high-intensity statin. Ezetimibe could also serve as an alternative treatment in cases of statin intolerance. In conclusion, ezetimibe has an excellent safety/tolerability profile; it is the first added treatment to a statin that can attain LDL-C targets. In the combined therapy, the hypolipidemic effect is enhanced while the dose of statin could be lower, thus limiting the occurrence of side-effects. Ezetimibe could also serve as an alternative mode of treatment in cases of statin intolerance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Effects of Quercetin on Blood Pressure: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Author

Serban, Maria‐Corina, Sahebkar, Amirhossein, Zanchetti, Alberto, Mikhailidis, Dimitri P, Howard, George, Antal, Diana, Andrica, Florina, Ahmed, Ali, Aronow, Wilbert S, Muntner, Paul, Lip, Gregory YH, Graham, Ian, Wong, Nathan, Rysz, Jacek, Banach, Maciej, and Group, for the Lipid and Blood Pressure Meta‐analysis Collaboration

Subjects
Prevention, Nutrition, Complementary and Integrative Health, Cardiovascular, Clinical Research, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Antioxidants, Blood Pressure, Humans, Quercetin, Randomized Controlled Trials as Topic, blood pressure, flavonoids, high blood pressure, hypertension, lipids, meta-analysis, nutrition, quercetin, Lipid and Blood Pressure Meta‐analysis Collaboration (LBPMC) Group, meta‐analysis, Cardiorespiratory Medicine and Haematology
Abstract

Quercetin, the most abundant dietary flavonol, has antioxidant effects in cardiovascular disease, but the evidence regarding its effects on blood pressure (BP) has not been conclusive. We assessed the impact of quercetin on BP through a systematic review and meta-analysis of available randomized controlled trials. We searched PUBMED, Cochrane Library, Scopus, and EMBASE up to January 31, 2015 to identify placebo-controlled randomized controlled trials investigating the effect of quercetin on BP. Meta-analysis was performed using either a fixed-effects or random-effect model according to I(2) statistic. Effect size was expressed as weighted mean difference (WMD) and 95% CI. Overall, the impact of quercetin on BP was reported in 7 trials comprising 9 treatment arms (587 patients). The results of the meta-analysis showed significant reductions both in systolic BP (WMD: -3.04 mm Hg, 95% CI: -5.75, -0.33, P=0.028) and diastolic BP (WMD: -2.63 mm Hg, 95% CI: -3.26, -2.01, P500 mg/day. Further studies are necessary to investigate the clinical relevance of these results and the possibility of quercetin application as an add-on to antihypertensive therapy.

Published
2016

35. Thyroid Disorders and Peripheral Arterial Disease

Author

Studen, Katica Bajuk, primary, Gaberscek, Simona, additional, Zaletel, Katja, additional, Blinc, Ales, additional, Sabovic, Miso, additional, Schernthaner, Gerit-Holger, additional, Anagnostis, Panagiotis, additional, Antignani, Pier Luigi, additional, Jensterle, Mojca, additional, Mikhailidis, Dimitri P., additional, and Poredos, Pavel, additional

Published
2023
Full Text
View/download PDF

36. An international, multispecialty, expert-based Delphi Consensus document on controversial issues in the management of patients with asymptomatic and symptomatic carotid stenosis

Author

Paraskevas, Kosmas I., primary, Mikhailidis, Dimitri P., additional, Ringleb, Peter Arthur, additional, Brown, Martin M., additional, Dardik, Alan, additional, Poredos, Pavel, additional, Gray, William A., additional, Nicolaides, Andrew N., additional, Lal, Brajesh K., additional, Mansilha, Armando, additional, Antignani, Pier Luigi, additional, de Borst, Gert J., additional, Cambria, Richard P., additional, Loftus, Ian M., additional, Lavie, Carl J., additional, Blinc, Ales, additional, Lyden, Sean P., additional, Matsumura, Jon S., additional, Jezovnik, Mateja K., additional, Bacharach, J. Michael, additional, Meschia, James F., additional, Clair, Daniel G., additional, Zeebregts, Clark J., additional, Lanza, Gaetano, additional, Capoccia, Laura, additional, Spinelli, Francesco, additional, Liapis, Christos D., additional, Jawien, Arkadiusz, additional, Parikh, Sahil A., additional, Svetlikov, Alexei, additional, Menyhei, Gabor, additional, Davies, Alun H., additional, Musialek, Piotr, additional, Roubin, Gary, additional, Stilo, Francesco, additional, Sultan, Sherif, additional, Proczka, Robert M., additional, Faggioli, Gianluca, additional, Geroulakos, George, additional, Fernandes e Fernandes, Jose, additional, Ricco, Jean-Baptiste, additional, Saba, Luca, additional, Secemsky, Eric A., additional, Pini, Rodolfo, additional, Myrcha, Piotr, additional, Rundek, Tatjana, additional, Martinelli, Ombretta, additional, Kakkos, Stavros K., additional, Sachar, Ravish, additional, Goudot, Guillaume, additional, Schlachetzki, Felix, additional, Lavenson, George S., additional, Ricci, Stefano, additional, Topakian, Raffi, additional, Millon, Antoine, additional, Di Lazzaro, Vincenzo, additional, Silvestrini, Mauro, additional, Chaturvedi, Seemant, additional, Eckstein, Hans-Henning, additional, Gloviczki, Peter, additional, and White, Christopher J., additional

Published
2023
Full Text
View/download PDF

38. Recent advances and controversial issues in the optimal management of asymptomatic carotid stenosis

Author

Paraskevas, Kosmas I., primary, Brown, Martin M., additional, Lal, Brajesh K., additional, Myrcha, Piotr, additional, Lyden, Sean P., additional, Schneider, Peter A., additional, Poredos, Pavel, additional, Mikhailidis, Dimitri P., additional, Secemsky, Eric A., additional, Musialek, Piotr, additional, Mansilha, Armando, additional, Parikh, Sahil A., additional, Silvestrini, Mauro, additional, Lavie, Carl J., additional, Dardik, Alan, additional, Blecha, Matthew, additional, Liapis, Christos D., additional, Zeebregts, Clark J., additional, Nederkoorn, Paul J., additional, Poredos, Peter, additional, Gurevich, Victor, additional, Jawien, Arkadiusz, additional, Lanza, Gaetano, additional, Gray, William A., additional, Gupta, Ajay, additional, Svetlikov, Alexei V., additional, Fernandes e Fernandes, Jose, additional, Nicolaides, Andrew N., additional, White, Christopher J., additional, Meschia, James F., additional, Cronenwett, Jack L., additional, Schermerhorn, Marc L., additional, and AbuRahma, Ali F., additional

Published
2023
Full Text
View/download PDF

39. Personalized Medicine for Cardiovascular Disease Risk in Artificial Intelligence Framework

Author

Singh, Manasvi, primary, Kumar, Ashish, additional, Khanna, Narendra N., additional, Laird, John R., additional, Nicolaides, Andrew, additional, Faa, Gavino, additional, Johri, Amer M., additional, Mantella, Laura E., additional, Fernandes, Jose, additional, Teji, Jagjit S., additional, Singh, Narpinder, additional, Fouda, Mostafa M., additional, Sharma, Aditya, additional, Kitas, George, additional, Rathore, Vijay, additional, Singh, Inder M., additional, Tadepalli, Kalyan, additional, Al-Maini, Mustafa, additional, Isenovic, Esma R., additional, Chaturvedi, Seemant, additional, Paraskevas, Kosmas I., additional, Mikhailidis, Dimitri P., additional, Viswanathan, Vijay, additional, Kalra, Manudeep K, additional, Ruzsa, Zoltan, additional, Saba, Luca, additional, Laine, Andrew F., additional, Bhatt, Deepak L., additional, and Suri, Jasjit S., additional

Published
2023
Full Text
View/download PDF

40. Carotid Plaque-RADS, a novel stroke risk classification system

Author

Saba, Luca, primary, Cau, Riccardo, additional, Murgia, Alessandro, additional, Nicolaides, Andrew N., additional, Wintermark, Max, additional, Castillo, Mauricio, additional, Staub, Daniel, additional, Kakkos, Stravos, additional, Yang, Qi, additional, Paraskevas, Kosmas I., additional, Yuan, Chun, additional, Edjlali, Myriam, additional, Sanfilippo, Roberto, additional, Hendrikse, Jeroen, additional, Johansson, Elias, additional, Mossa-Basha, Mamood, additional, Balu, Niranjan, additional, Dichgans, Martin, additional, Saloner, David, additional, Bos, Daniel, additional, Jager, Rolf H., additional, Naylor, Ross, additional, Faa, Gavino, additional, Suri, Jasjit S., additional, Costello, Justin, additional, Auer, Dorothee P., additional, McNally, Scott, additional, Bonati, Leo H., additional, Nardi, Valentina, additional, van der Lugt, Aad, additional, Griffin, Maura, additional, Wasserman, Bruce A., additional, Kooi, M. Eline, additional, Gillard, Jonathan, additional, Lanzino, Giuseppe, additional, Mikhailidis, Dimitri P., additional, Mandell, Danny M., additional, Benson, John, additional, van Dam-Nolen, Dianne, additional, Kopczak, Anna, additional, Song, Jae, additional, Gupta, Ajay, additional, DeMarco, J. Kevin, additional, Chaturvedi, Seemant, additional, Virmani, Renu, additional, Hatsukami, Tom, additional, Brown, Martin, additional, Moody, Alan R., additional, Libby, Peter, additional, Schindler, Andreas, additional, and Saam, Tobias, additional

Published
2023
Full Text
View/download PDF

50. Cardiometabolic Risk, Peripheral Arterial Disease and Cardiovascular Events in Polycystic Ovary Syndrome: Time to Implement Systematic Screening and Update the Management

Author

Janez, Andrej, primary, Herman, Rok, additional, Poredos, Pavel, additional, Mikhailidis, Dimitri P., additional, Blinc, Ales, additional, Sabovic, Miso, additional, Studen, Katica Bajuk, additional, Jezovnik, Mateja Kaja, additional, Schernthaner, Gerit-Holger, additional, Anagnostis, Panagiotis, additional, Antignani, Pier Luigi, additional, and Jensterle, Mojca, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results